Chaga

Metadata

Regulatory Status

European Regulatory Bodies

Chaga has not been assessed by any major European phytotherapy regulatory body:

• Commission E (Germany): No monograph exists. Chaga was not part of the European herbal tradition evaluated during the Commission E program (1978-1994).
• ESCOP: No monograph. Not within the scope of European scientific cooperative assessment.
• EMA/HMPC: No assessment report or monograph. Inonotus obliquus does not appear in the EU Community Herbal Monograph program.

Novel Food (EU)

Chaga preparations may require Novel Food authorization under Regulation (EU) 2015/2283 when marketed as concentrated extracts with health claims. Some EU member states accept the whole mushroom as having a history of consumption, but regulatory status varies by country and preparation type.

Russian Pharmacopoeia (Historical)

In 1955, the USSR Ministry of Health officially recognized Inonotus obliquus and included it in the Soviet Pharmacopoeia as Befungin (Befunginum), an alcohol-based chaga extract with added cobalt salts. Befungin was registered for gastritis, gastric/duodenal ulcers, gastric polyposis, and as a symptomatic agent in oncology. Befungin remains available over-the-counter in Russia. This registration was based on traditional use, not randomized controlled trials.

Chinese Pharmacopoeia

Chaga is not listed in the Chinese Pharmacopoeia (2020 edition). While Inonotus obliquus grows in northern China and has been studied by Chinese researchers, it does not hold official pharmacopoeia status in TCM. Its inclusion in the TCM tradition listed here reflects its use by Chinese integrative practitioners and growing research interest, not classical pharmacopoeia recognition.

United States

Chaga is sold as a dietary supplement under DSHEA. It has no FDA GRAS status. The FDA has not evaluated chaga for any therapeutic claim.

Health Canada

Permits chaga as a Natural Health Product ingredient with the limited claim “source of fungal polysaccharides with immunomodulating properties” and recommends a maximum daily intake of 3.6 g of raw material.

Conditions & Indications

No Conditions with Human Clinical Trial Evidence

There are no published randomized controlled trials of chaga in humans for any indication. This is the central limitation of the chaga evidence base. All conditions listed below are supported only by preclinical data (in vitro and animal studies) or traditional use.

Preclinical Evidence Only

Antioxidant Activity

Chaga extracts demonstrate exceptionally high antioxidant capacity in standard in vitro assays (DPPH, ABTS, FRAP). The melanin complex (constituting up to 30% of sclerotium dry weight), polyphenolic compounds, and SOD content contribute to this activity. However, in vitro antioxidant assays do not reliably predict in vivo effects in humans. The frequently cited claim of the “highest ORAC score of any natural food” lacks verifiable sourcing.

Immune Modulation

Chaga polysaccharides activate macrophages via TLR2 and TLR4 signaling, inducing secretion of TNF-alpha, IL-6, and nitric oxide. In combination with interferon-gamma, they stimulate IL-12p70 production, a key cytokine for anti-tumor immune responses. Beta-glucans enhance NK cell activity and promote dendritic cell maturation in animal models (Wold et al., 2024).

Anti-inflammatory Activity

Inotodiol, lanosterol, and trametenolic acid inhibit NF-kB/p65 signaling and reduce pro-inflammatory cytokine production in LPS-stimulated macrophage models (Van et al., 2009). Oral chaga extract inhibited LPS-induced NF-kB activation in mice.

Cytotoxic Activity

Betulinic acid demonstrates direct cytotoxicity against multiple cancer cell lines through mitochondrial-mediated apoptosis induction (Gery et al., 2018). Chaga polysaccharides and triterpenoids show anti-proliferative activity against colorectal (HCT-116), breast, lung (A549), and hepatoma cell lines in vitro. No in vivo anti-tumor efficacy has been demonstrated in humans.

Anti-diabetic Activity

Chaga polysaccharides reduced postprandial blood glucose in diabetic mouse models by inhibiting alpha-amylase and alpha-glucosidase. Betulinic acid showed hypoglycemic effects in high-fat-diet-induced obese mice.

Traditional Uses (Siberian and Russian Folk Medicine)

• Gastrointestinal disorders: Gastritis, ulcers, polyposis — the primary indications codified in the Soviet Pharmacopoeia as Befungin
• Cancer: General folk remedy for tumors, particularly stomach and colorectal cancers, across Russian, Polish, and Baltic traditions
• General tonic: Daily beverage (decoction) for health maintenance, especially among Khanty and Siberian peoples
• Tuberculosis: Used by Khanty people and Siberian practitioners for pulmonary tuberculosis

Mechanism of Action

1. Melanin-Mediated Radical Scavenging

The black exterior of the chaga sclerotium contains high concentrations of melanin pigments (up to 30% of dry weight). This melanin is a complex of fungal and birch-derived subunits that acts as a broad-spectrum free radical scavenger, neutralizing superoxide, hydroxyl, and peroxyl radicals. Additionally, chaga contains substantial quantities of superoxide dismutase (SOD), which catalyzes the dismutation of superoxide anion radicals. The combined melanin-SOD-polyphenol system accounts for chaga’s exceptional performance in in vitro antioxidant assays.

2. Beta-Glucan Polysaccharide Immune Activation

Water-soluble polysaccharides, primarily beta-(1,3)-D-glucans with (1,6) branching, activate innate immune cells through pattern recognition receptors. Two well-characterized fractions (AcF1 and AcF3) are potent TLR2 and TLR4 agonists on macrophages, triggering MyD88-dependent signaling cascades leading to NF-kB activation and cytokine secretion. These polysaccharides are notably weaker Dectin-1 agonists compared to beta-glucans from reishi or turkey tail, suggesting a distinct immunological activation profile (Wold et al., 2024).

3. Betulinic Acid Bioactivity

Betulin and betulinic acid are pentacyclic triterpenoids that chaga concentrates from its birch bark substrate — they are not synthesized by the fungus itself, which is why birch-grown chaga is considered pharmacologically distinct from chaga growing on other tree species. Betulinic acid triggers apoptosis in cancer cells through a direct effect on mitochondrial membranes, inducing cytochrome c release and caspase activation. It also inhibits alpha-amylase, promotes insulin secretion, and demonstrates hypoglycemic activity in animal models.

4. Triterpenoid Anti-inflammatory Activity

Lanostane-type triterpenoids (inotodiol, lanosterol, trametenolic acid) inhibit NF-kB nuclear translocation and downstream pro-inflammatory cytokine production. Inotodiol, the most abundant at approximately 0.2% of dry weight, induces atypical dendritic cell maturation, suggesting nuanced immunomodulatory activity beyond simple immunostimulation.

Key Pharmacological Note

Hot-water extraction is necessary to release beta-glucan polysaccharides from the chitin cell wall matrix. Ethanol extraction captures the alcohol-soluble triterpenoids (inotodiol, betulinic acid, lanosterol). Dual extraction provides the broadest spectrum of bioactive compounds. Raw, unextracted chaga powder delivers significantly fewer bioavailable compounds.

Clinical Evidence Summary

Human Clinical Trials

There are no published randomized, double-blind, placebo-controlled clinical trials of chaga in humans for any indication. This statement, current as of February 2026, is the most important fact in this monograph. A 2021 review (Szychowski et al., Journal of Traditional and Complementary Medicine) confirmed that while therapeutic effects of chaga components are well characterized in vitro, effects in vivo in humans remain unverified. A 2024 review (Kaczmarczyk-Ziemba et al., Mycology) confirmed extensive preclinical evidence across multiple activity domains but noted the complete absence of rigorous clinical data.

Preclinical Evidence Summary

Evidence Comparison with Other Medicinal Mushrooms

Chaga’s evidence gap is notable when compared with related species. Reishi has a Cochrane systematic review of five RCTs. Lion’s Mane has published RCTs for cognitive function (Mori et al., 2009). Turkey Tail PSK/PSP are approved as adjunctive cancer therapy in Japan with clinical trial support. Chaga stands alone among major medicinal mushrooms with zero human clinical trials.

Safety Profile

General Assessment

Chaga has been consumed as a decoction in Russian and Scandinavian communities for centuries without widespread reports of acute toxicity. However, systematic safety data from controlled human studies is absent. The primary documented safety concern is oxalate nephropathy.

Oxalate Nephropathy Risk

This is the most serious documented adverse effect. Chaga sclerotium contains very high concentrations of oxalic acid. Excessive oral intake leads to hyperoxaluria and calcium oxalate crystal deposition in renal tubules:

• Kikuchi et al. (2014): A 72-year-old woman developed oxalate nephropathy after consuming chaga powder (4-5 teaspoons/day) for 6 months. Kidney biopsy confirmed calcium oxalate deposits.
• Lee et al. (2020): A 49-year-old man developed end-stage renal disease after long-term chaga ingestion. The chaga material contained 14.2 g oxalate per 100 g dry weight. The patient required long-term dialysis.
• Kim et al. (2022): A 69-year-old man consuming 10-15 g/day for 3 months developed acute oxalate nephropathy with nephrotic syndrome, requiring hemodialysis.

Drug Interactions

No clinically significant drug interactions have been documented in human studies. Theoretical considerations based on preclinical data include:

• Anticoagulants/antiplatelets: In vitro platelet aggregation inhibition suggests theoretical additive effect, though no human cases are reported.
• Antidiabetic agents: Animal-model hypoglycemic effects suggest theoretical additive blood glucose lowering.
• Immunosuppressants: Beta-glucan immune stimulation could theoretically counteract immunosuppressive therapy.

Side Effects

• Common (at traditional tea doses): Generally well-tolerated based on traditional use history
• Uncommon: Mild gastrointestinal discomfort (nausea, bloating)
• Serious: Oxalate nephropathy at high doses or prolonged use (see above)

Contraindications

• Active kidney disease or history of calcium oxalate kidney stones (high oxalate content)
• Autoimmune conditions (immunostimulatory beta-glucans could theoretically exacerbate)
• Pre-surgical: discontinue at least 2 weeks before elective surgery

Clinical Dosage

Important Caveat

Because no human clinical trials exist, there are no evidence-based dosage recommendations for chaga. All dosage information below is derived from traditional use, the Russian Pharmacopoeia (Befungin), and Health Canada guidance.

Traditional Decoction

• Method: Dried chaga chunks simmered below 80 degrees C for 1-4 hours
• Dose: 1-3 cups daily, prepared from approximately 5-10 g of dried material
• Siberian practice: Chunks were reused for multiple decoctions until the liquid no longer darkened

Befungin (Russian Pharmacopoeia)

• Formulation: Alcohol-based concentrated chaga extract with cobalt salts
• Dose: 3 tablespoons diluted in 150 mL warm water, 3 times daily before meals
• Duration: Courses of 3-5 months with breaks between courses

Modern Supplement Forms

• Dried powder: 1,000-3,000 mg/day in divided doses (Health Canada suggests not exceeding 3.6 g/day)
• Hot-water extract: 300-1,000 mg/day, depending on extraction ratio
• Dual extract (water + ethanol): 1-3 mL tincture, 1-3 times daily

Extraction Considerations

Hot-water extraction releases beta-glucan polysaccharides from the chitin matrix. Ethanol extraction captures triterpenoids (inotodiol, betulinic acid). Dual extraction provides the broadest bioactive spectrum. Raw powder has significantly lower bioavailability than extracted preparations.

Sources

• Szychowski KA, Skora B, Pomianek T, Gminski J. Inonotus obliquus — from folk medicine to clinical use. J Tradit Complement Med. 2021;11(4):293-302
• Kaczmarczyk-Ziemba A, Kijowska I, Przybyla M. Therapeutic properties of Inonotus obliquus (Chaga mushroom): A review. Mycology. 2024;15(2):160-178
• Glamoclija J, Cirkovic Velickovic T, Petrovic J. A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms. Heliyon. 2024;10(16):e35665
• Gery A, Dubreule C, Andre V, et al. Chaga (Inonotus obliquus), a future potential medicinal fungus in oncology? A chemical study and a comparison of the cytotoxicity against human lung adenocarcinoma cells (A549) and human bronchial epithelial cells (BEAS-2B). Integr Cancer Ther. 2018;17(3):832-843
• Wold CW, Gerber H, Engstad RE, Inngjerdingen KT. Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce macrophage anti-cancer activity. Commun Biol. 2024;7:222
• Pan HH, Yu XT, Li T, et al. Aqueous extract from a Chaga medicinal mushroom prevents herpes simplex virus entry through inhibition of viral-induced membrane fusion. Int J Med Mushrooms. 2013;15(1):29-38
• Kikuchi Y, Seta K, Ogawa Y, et al. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol. 2014;81(6):440-444
• Lee SS, Lee S, Lee SH, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom. J Korean Med Sci. 2020;35(19):e122
• Kim YR, Park YJ, Jang HR. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome. Medicine. 2022;101(10):e29010
• Van Q, Nayak BN, Reimer M, et al. Anti-inflammatory effect of Inonotus obliquus, Polygala senega L., and Viburnum trilobum in a cell screening assay. J Ethnopharmacol. 2009;125(3):487-493
• Shikov AN, Pozharitskaya ON, Makarov VG, et al. Medicinal plants of the Russian Pharmacopoeia; their history and applications. J Ethnopharmacol. 2014;154(3):481-536
• Zhong XH, Ren K, Lu SJ, et al. Progress of research on Inonotus obliquus. Chin J Integr Med. 2009;15(2):156-160
• Memorial Sloan Kettering Cancer Center. Chaga Mushroom monograph. mskcc.org (accessed February 2026)

Connections

• Compare with Reishi — the closest comparator among medicinal mushrooms; both contain immunomodulatory beta-glucans and bioactive triterpenoids, but reishi has clinical trial evidence (Cochrane review) that chaga entirely lacks
• Compare with Turkey Tail — PSK/PSP polysaccharide extracts represent what clinical validation of mushroom immunomodulators looks like, providing a benchmark for what chaga has not achieved
• Chaga’s betulinic acid is not synthesized by the fungus but concentrated from the birch bark substrate, making host tree species a critical determinant of pharmacological profile
• The melanin-SOD-polyphenol antioxidant system in chaga is mechanistically distinct from the triterpenoid and polysaccharide bioactivity of other medicinal mushrooms, positioning it uniquely in the antioxidant-longevity category
• Despite enormous consumer popularity and marketing claims, chaga has the weakest clinical evidence base among the major medicinal mushrooms — a disconnect between commercial reality and scientific substantiation that merits emphasis